CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

Near Add Your Location

Sorting 15 by

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator
Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
  • Accepting patients
  • Show Principal Investigator
Duke Cancer Center
Duke University Medical Center
Durham, NC
  • Accepting patients
  • Show Principal Investigator
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
  • Show Principal Investigator
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
  • Show Principal Investigator
University of Colorado Cancer Center
Anschutz Cancer Pavilion
Aurora, CO
  • Accepting patients
  • Show Principal Investigator
Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
  • Accepting patients
  • Show Principal Investigator
Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
  • Accepting patients
  • Show Principal Investigator
UK Markey Cancer Center
University of Kentucky
Lexington, KY
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.